Deutsche Bank Comments on Potential Teva (TEVA)/ Mylan (MYL) Deal
Tweet Send to a Friend
Deutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) with a price target of $67. Analyst Gregg Gilbert ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
